Compare Bristol-Myers Squibb Co (BMY) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.39 (market cap $116.30B), while T-Rex 2X Long MSTR Daily Target ETF trades at $2.02. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| BMY | MSTU | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.37 | $106.80 |
52-Week Low | $42.60 | $1.46 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
MSTU (T-REX 2X Long MSTR Daily Target ETF) trades at $1.78, down 5.07% today amid significant bearish technical signals. The leveraged ETF tracking MicroStrategy has experienced extreme volatility, with news reports indicating a 95% decline over the past year. Technical indicators show overwhelming bearish momentum with moving averages unanimously negative, while fundamental data remains unavailable for this specialized leveraged product.
The outlook remains highly speculative given the ETF's leveraged structure and dependence on MicroStrategy's Bitcoin-heavy strategy. Investment opportunity exists only for sophisticated traders comfortable with extreme volatility, while risks include daily rebalancing decay, concentration in a single stock, and amplified losses during market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
